Company Dynamic

Novartis is trying to do everything possible to keep a generic version of its blockbuster heart failure drug Entresto off the U.S. market. Despite numerous legal hurdles, the company has failed to gain regulatory approval.

On October 15, 2024, TRIANA Biomedicines announced a major announcement that it has entered into a strategic collaboration and licensing agreement with world-renowned pharmaceutical giant Pfizer.

Braskem, a global biopolymer producer, and SCG Chemicals, a leading petrochemical company in Thailand and Southeast Asia, have signed a joint venture agreement to establish Braskem Siam Company Limited.

• Braskem
• SCG Chemicals

IMCD, a leading global distributor of specialty chemicals and ingredients, has announced the opening of a new microbiology laboratory in Jakarta, Indonesia.

• IMCD

Safic-Alcan announces a new distribution partnership with Carbon Waters, an innovative French startup focused on advanced sustainable additives.

• Safic-Alcan
• Carbon Waters

BASF has expanded its biological solutions offering with the introduction of seaweed biostimulants from Acadian Plant Health, a leading marine plant harvesting, cultivation and ingredient extraction company based in Dartmouth, Canada.

• BASF
• Acadian

The British government is planning a study to assess whether a new weight-loss drug from US pharmaceutical giant Eli Lilly can help people regain their ability to work and have a positive impact on tackling high rates of long-term disease.

Johnson & Johnson raised its 2024 profit and sales forecast on Tuesday, following strong oncology drug sales and quarterly results that beat Wall Street expectations.

The plasticizer dioctyl phthalate (DOP) market showed a trend of jumping high and going high, and its rising power mainly came from the cost support brought by the tight supply of octanol and the rising price.

The time frame for this investigation is set to be the dumping investigation period from July 1, 2023 to June 30, 2024, while the injury investigation period covers the period from January 1, 2021 to June 30, 2024.

Mitsubishi Chemical Group has decided to expand the production capacity of ion exchange resins at its Fukuoka Plant in Kitakyushu, Japan. The upgraded facility is scheduled to be operational in April 2026.

• Mitsubishi chemical

BASF has received funding approval from German government agencies to build the world's most powerful industrial heat pump. In the coming months, the company will carry out construction preparations at the Ludwigshafen plant.

• BASF

Azelis is pleased to announce a new distribution agreement with Gattefossé, a leading global developer and manufacturer of pharmaceutical excipients and natural cosmetic ingredients serving the global beauty and wellness industry.

• Azelis
• Gattefossé

Bayer AG (BAYGn.DE) announced on Monday that it has submitted an application to the European Union's drug regulator for approval of its product Nubeqa, also known as darolutamide, in combination with androgen deprivation therapy (ADT).

In Monday's deal, Vanda Pharmaceutical Inc categorically rejected a second takeover proposal from Britain's Cycle Pharmaceuticals that valued the company at $8 per share.

With this injection of capital, PPG Coatings (Tianjin) Co., Ltd. aims to further expand its product line, develop new products to meet the changing market needs, and actively explore new market areas.

Idemitsu Kosan and Mitsui Chemicals have been exploring ways to optimize production by integrating their ethylene complex in Chiba. After completing a feasibility study (FS), the two companies are now entering the next phase: FEED.

• Idemitsu Kosan
• Mitsui chemicals

Givaudan, a global leader in Taste & Wellbeing, recently completed the groundbreaking ceremony for a new factory in Cikarang, Indonesia.

• Givaudan

BASF's petrochemical division has completed the upgrade of its superabsorbent polymer (SAP) plant in Freeport, Texas, with an investment of US$19.2 million to date.

• BASF
• superabsorbent polymer

Six months after successfully winning U.S. Food and Drug Administration (FDA) approval for Beqvez, a gene therapy to treat hemophilia B, Pfizer is once again on the cusp of another important product indication approval.